Advanced search
Publication Cover
Bioanalysis Volume 2, 2010 - Issue 7
Submit an article Journal homepage
531
Views
1
CrossRef citations to date
0
Altmetric
Review

Production of Human Phase 1 and 2 Metabolites by Whole-Cell Biotransformation with Recombinant Microbes

Andy Zöllner1 PomBioTech GmbH, Campus A1-1, D-66123Saarbrücken, Germany. [email protected]
,
Daniela Buchheit1 PomBioTech GmbH, Campus A1-1, D-66123Saarbrücken, Germany. [email protected]
,
Markus R Meyer2 Department of Experimental and Clinical Toxicology, Saarland University, Building 46, D-66421Homburg (Saar), Germany
,
Hans H Maurer2 Department of Experimental and Clinical Toxicology, Saarland University, Building 46, D-66421Homburg (Saar), Germany
,
Frank T Peters3 Institute of Forensic Medicine, Friedrich Schiller University of Jena, Fürstengraben 23, D-07740Jena, Germany
&
Matthias Bureik1 PomBioTech GmbH, Campus A1-1, D-66123Saarbrücken, Germany. [email protected]Correspondence[email protected]
Pages 1277-1290 | Published online: 13 Jul 2010

Bibliography

  • Thompson TN . Safety testing of drug metabolites. In:Annual Reports in Medicinal Chemistry. Macor JE (Ed.). Academic Press, London, UK (2009).
  • Davis-Bruno KL , AtrakchiA. A regulatory perspective on issues and approaches in characterizing human metabolites. Chem. Res. Toxicol. 19(12), 1561–1563 (2006).
  • US FDA. Guidance for industry: safety testing of drug metabolites. (2008).
  • Bernhardt R . Cytochrome P450: structure, function, and generation of reactive oxygen species. Rev. Physiol. Biochem. Pharmacol. 127, 137–221 (1996).
  • Bernhardt R . Cytochromes P450 as versatile biocatalysts. J. Biotechnol. 124(1), 128–145. (2006).
  • Guengerich FP . Cytochrome P450: what have we learned and what are the future issues? Drug Metab. Rev. 36(2), 159–197 (2004).
  • Hannemann F , BichetA, EwenKM, BernhardtR. Cytochrome P450 systems-biological variations of electron transport chains. Biochim. Biophys. Acta1770(3), 330–344 (2006).
  • Nebert DW , DaltonTP. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat. Rev. Cancer6(12), 947–960 (2006).
  • Omura T , SatoR. A new cytochrome in liver microsomes. J. Biol. Chem. 237, 1375–1376 (1962).
  • Stark K , GuengerichFP. Characterization of orphan human cytochromes P450. Drug Metab. Rev. 39(2–3), 627–637 (2007).
  • Julsing MK , CornelissenS, BuhlerB, SchmidA. Heme-iron oxygenases: powerful industrial biocatalysts? Curr. Opin. Chem. Biol. 12(2), 177–186 (2008).
  • Yamazaki H , NakajimaM, NakamuraMet al. Enhancement of cytochrome P450 3A4 catalytic activities by cytochrome b5 in bacterial membranes. Drug Metab. Dispos. 27(9), 999–1004 (1999).
  • Vail RB , HomannMJ, HannaI, ZaksA. Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with nadph-P450 reductase expressed in Escherichia coli. J. Ind. Microbiol. Biotechnol. 32(2), 67–74 (2005).
  • Kolar NW , SwartAC, MasonJI, SwartP. Functional expression and characterisation of human cytochrome P45017 α in pichia pastoris. J. Biotechnol. 129(4), 635–644 (2007).
  • Soars MG , McginnityDF, GrimeK, RileyRJ. The pivotal role of hepatocytes in drug discovery. Chem. Biol. Interact. 168(1), 2–15 (2007).
  • Gonzalez FJ , CrespiCL, GelboinHV. DNA-expressed human cytochrome P450s: a new age of molecular toxicology and human risk assessment. Mutat. Res. 247(1), 113–127 (1991).
  • Buters JT , KorzekwaKR, KunzeKL, OmataY, HardwickJP, GonzalezFJ. CDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus. Drug Metab. Dispos. 22(5), 688–692 (1994).
  • Peters FT , BureikM, MaurerHH. Biotechnological synthesis of drug metabolites using human cytochrome P450 isozymes heterologously expressed in fission yeast. Bioanalysis1(4), 821–830 (2009).
  • Shaw PM , HoseaNA, ThompsonDV, LeniusJM, GuengerichFP. Reconstitution premixes for assays using purified recombinant human cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b5. Arch. Biochem. Biophys. 348(1), 107–115 (1997).
  • Guengerich FP . Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 14(6), 611–650 (2001).
  • Kim DH , KimKH, IsinEMet al. Heterologous expression and characterization of wild-type human cytochrome P450 1a2 without conventional N-terminal modification in Escherichia coli. Protein Expr. Purif. 57(2), 188–200 (2008).
  • Zmijewski M , GillespieTA, JacksonDA, SchmidtDF, YiP, KulanthaivelP. Application of biocatalysis to drug metabolism: preparation of mammalian metabolites of a biaryl-bis-sulfonamide ampa (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptor potentiator using actinoplanes missouriensis. Drug Metab. Dispos. 34(6), 925–931 (2006).
  • Yun CH , YimSK, KimDH, AhnT. Functional expression of human cytochrome P450 enzymes in escherichia coli. Curr. Drug Metab. 7(4), 411–429 (2006).
  • Van Beilen JB , HoltackersR, LuscherD, BauerU, WitholtB, DuetzWA. Biocatalytic production of perillyl alcohol from limonene by using a novel Mycobacterium sp cytochrome P450 alkane hydroxylase expressed in pseudomonas putida. Appl. Environ. Microbiol. 71(4), 1737–1744 (2005).
  • Fujita K , KamatakiT. Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered salmonella typhimurium yg7108 expressing each form of CYP together with human nadph-cytochrome P450 reductase. Mutat. Res. Fund. Mol. Mech. Mut. 483(1–2), 35–41 (2001).
  • Rushmore TH , ReiderPJ, SlaughterD, AssangC, ShouM. Bioreactor systems in drug metabolism: synthesis of cytochrome P450-generated metabolites. Metab. Eng. 2(2), 115–125 (2000).
  • Harnastai IN , GilepAA, UsanovSA. The development of an efficient system for heterologous expression of cytochrome P450s in Escherichia coli using heme gene coexpression. Protein Expr. Purif. 46(1), 47–55 (2006).
  • Uchida E , KagawaN, SakakiTet al. Purification and characterization of mouse CYP27B1 overproduced by an escherichia coli system coexpressing molecular chaperonins groel/es. Biochem. Biophys. Res. Commun. 323(2), 505–511 (2004).
  • Zollner A , KagawaN, WatermanMRet al. Purification and functional characterization of human 11β hydroxylase expressed in Escherichia coli. FEBS J. 275(4), 799–810 (2008).
  • Narhi LO , FulcoAJ. Identification and characterization of two functional domains in cytochrome P450BM-3, a catalytically self-sufficient monooxygenase induced by barbiturates in bacillus megaterium. J. Biol. Chem. 262(14), 6683–6690 (1987).
  • Noble MA , MilesCS, ChapmanSKet al. Roles of key active-site residues in flavocytochrome P450 BM3. Biochem. J. 339, 371–379 (1999).
  • Otey CR , BandaraG, LalondeJ, TakahashiK, ArnoldFH. Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450. Biotechnol. Bioeng. 93(3), 494–499 (2006).
  • Schwaneberg U , OteyC, CirinoPC, FarinasE, ArnoldFH. Cost-effective whole-cell assay for laboratory evolution of hydroxylases in Escherichia coli. J. Biomol. Screen6(2), 111–117 (2001).
  • Hamann T , MollerBL. Improved cloning and expression of cytochrome P450s and cytochrome P450 reductase in yeast. Protein Expr. Purif. 56(1), 121–127 (2007).
  • Bureik M , SchifflerB, HiraokaY, VogelF, BernhardtR. Functional expression of human mitochondrial CYP11B2 in fission yeast and identification of a new internal electron transfer protein, etp1. Biochemistry41(7), 2311–2321 (2002).
  • Peyronneau MA , RenaudJP, TruanG, UrbanP, PomponD, MansuyD. Optimization of yeast-expressed human liver cytochrome P450 3A4 catalytic activities by coexpressing nadph-cytochrome P450 reductase and cytochrome b5. Eur. J. Biochem. 207(1), 109–116 (1992).
  • Goffeau A , BarrellBG, BusseyHet al. Life with 6000 genes. Science274(5287), 546, 563–7 (1996).
  • De Schutter K , LinYC, TielsPet al. Genome sequence of the recombinant protein production host pichia pastoris. Nat. Biotechnol. 27(6), 561–566 (2009).
  • Alfa C , FantesP, HyamsJ, McleodM, WarbrickE. Experiments with fission yeast. A laboratory course manual. Cold Spring Harbor Press, Cold Spring Harbor, NY, USA (1993).
  • Sambrook J , RusellDW. Molecular cloning: A laboratory manual. CSHL Press, Woodbury, NY, USA (2001).
  • Cereghino JL , CreggJM. Heterologous protein expression in the methylotrophic yeast pichia pastoris. FEMS Microbiol Rev. 24(1), 45–66 (2000).
  • Cereghino GPL , CereghinoJL, IlgenC, CreggJM. Production of recombinant proteins in fermenter cultures of the yeast pichia pastoris. Curr. Opin. Biotechnol. 13(4), 329–332 (2002).
  • Peters FT , DraganCA, WildeDRet al. Biotechnological synthesis of drug metabolites using human cytochrome P450 2D6 heterologously expressed in fission yeast exemplified for the designer drug metabolite 4´-hydroxymethyl- α-pyrrolidinobutyrophenone. Biochem. Pharmacol. 74(3), 511–520 (2007).
  • Peters FT , DraganCA, SchwaningerAEet al. Use of fission yeast heterologously expressing human cytochrome P450 2B6 in biotechnological synthesis of the designer drug metabolite N-(1-phenylcyclohexyl)-2-hydroxyethanamine. Forensic Sci. Int. 184, 69–73 (2009).
  • Dumas B , PomponD, ChandelierFet al. Total biosynthesis of hydrocortisone from a simple carbon source in yeast. Yeast20, S220–S220 (2003).
  • Szczebara FM , ChandelierC, VilleretCet al. Total biosynthesis of hydrocortisone from a simple carbon source in yeast. Nat. Biotechnol. 21(2), 143–149 (2003).
  • Dragan CA , BlankLM, BureikM. Increased tca cycle activity and reduced oxygen consumption during cytochrome P450-dependent biotransformation in fission yeast. Yeast23(11), 779–794 (2006).
  • Dragan CA , HartmannRW, BureikM. A fission yeast based test system for the determination of ic50 values of antiprostate tumor drugs acting on CYP21. J. Enzyme Inhib. Med. Chem. 21(5), 547–556 (2006).
  • Dragan CA , ZearoS, HannemannF, BernhardtR, BureikM. Efficient conversion of 11-deoxycortisol to cortisol (hydrocortisone) by recombinant fission yeast schizosaccharomyces pombe. FEMS Yeast Res. 5, 621–625 (2005).
  • Peters FT , DraganCA, KauffelsAet al. Biotechnological synthesis of the designer drug metabolite 4‘-hydroxymethyl-α-pyrrolidinohexanophenone in fission yeast heterologously expressing human cytochrome P450 2D6-A versatile alternative to multistep chemical synthesis. J. Anal. Toxicol. 33(4), 190–197 (2009).
  • Zöllner A , DraganCA, PistoriusDet al. Human CYP4Z1 catalyzes the in-chain hydroxylation of lauric acid and myristic acid. Biol. Chem. 390, 313–317 (2009).
  • Zollner A , ParrMK, DraganCAet al. CYP21-catalyzed production of the long-term urinary metandienone metabolite 17β-hydroxymethyl-17α-methyl-18-norandrosta-1,4,13-trien-3-one: a contribution to the fight against doping. Biol. Chem. 391(1), 119–127 (2010).
  • Peters FT , SchwaningerAE, DraganCA, BureikM, MaurerHH. New fission yeast strains expressing human cytochrome P450 enzymes to be used for biotechnological synthesis of drug metabolites. Ther. Drug. Monit. 29(4), 466–467 (2007).
  • Peters FT , SchwaningerAE, SauerCet al. Isolation and purification of the designer drug metabolite O-desethyl-N-(1-phenylcyclohexyl)-3-ethoxypropanamine (O-desethyl-pcepa) biotechnologically synthesized using fission yeast expressing CYP2D6. Presente at:XV. GTFCh–Symposium. Mosbach, Germany, 18–21 April 2007.
  • Iwata H , FujitaK, KushidaHet al. High catalytic activity of human cytochrome P450 coexpressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochem. Pharmacol. 55(8), 1315–1325 (1998).
  • Blake JAR , PritchardM, DingSHet al. Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli. FEBS Lett. 397(2–3), 210–214 (1996).
  • Chang MCY , EachusRA, TrieuW, RoDK, KeaslingJD. Engineering Escherichia coli for production of functionalized terpenoids using plant P450s. Nat. Chem. Biol. 3(5), 274–277 (2007).
  • Hummel W . New alcohol dehydrogenases for the synthesis of chiral compounds. Adv. Biochem. Eng. Biotechnol. 58, 145–184 (1997).
  • Bronley-Delancey A , McmillanDC, McmillanJM, JollowDJ, MohrLC, HoelDG. Application of cryopreserved human hepatocytes in trichloroethylene risk assessment: relative disposition of chloral hydrate to trichloroacetate and trichloroethanol. Environ. Health Perspect. 114(8), 1237–1242 (2006).
  • Griffin DR , GainerJL, CartaG. Asymmetric ketone reduction with immobilized yeast in hexane: biocatalyst deactivation and regeneration. Biotechnol. Prog. 17(2), 304–310 (2001).
  • Yu MA , WeiYM, ZhaoL, JiangL, ZhuXB, QiW. Bioconversion of ethyl 4-chloro-3-oxobutanoate by permeabilized fresh brewer’s yeast cells in the presence of allyl bromide. J. Ind. Microbiol. Biotechnol. 34(2), 151–156 (2007).
  • Katzberg M , WechlerK, MullerMet al. Biocatalytical production of (5s)-hydroxy-2-hexanone. Org. Biomol. Chem. 7(2), 304–314 (2009).
  • Stampfer W , KosjekB, FaberK, KroutilW. Biocatalytic asymmetric hydrogen transfer employing Rhodococcus ruber DSM 44541. J. Org. Chem. 68(2), 402–406 (2003).
  • Stampfer W , KosjekB, KroutilW, FaberK. On the organic solvent and thermostability of the biocatalytic redox system of rhodococcus ruber DSM 44541. Biotechnol. Bioeng. 81(7), 865–869 (2003).
  • Yamamoto H , MatsuyamaA, KobayashiY. Synthesis of ethyl (r)-4-chloro-3-hydroxybutanoate with recombinant escherichia coli cells expressing (s)-specific secondary alcohol dehydrogenase. Biosci. Biotechnol. Biochem. 66(2), 481–483 (2002).
  • Yamamoto H , MatsuyamaA, KobayashiY. Synthesis of (r)-1,3-butanediol by enantioselective oxidation using whole recombinant Escherichia coli cells expressing (s)-specific secondary alcohol dehydrogenase. Biosci. Biotechnol. Biochem. 66(4), 925–927 (2002).
  • Ernst M , KaupB, MullerM, Bringer-MeyerS, SahmH. Enantioselective reduction of carbonyl compounds by whole-cell biotransformation, combining a formate dehydrogenase and a (r)-specific alcohol dehydrogenase. Appl. Microbiol. Biotechnol. 66(6), 629–634 (2005).
  • Weckbecker A , HummelW. Improved synthesis of chiral alcohols with Escherichia coli cells coexpressing pyridine nucleotide transhydrogenase, NADP+-dependent alcohol dehydrogenase and NAD+-dependent formate dehydrogenase. Biotechnol. Lett. 26(22), 1739–1744 (2004).
  • Goldberg K , EdeggerK, KroutilW, LieseA. Overcoming the thermodynamic limitation in asymmetric hydrogen transfer reactions catalyzed by whole cells. Biotechnol. Bioeng. 95(1), 192–198 (2006).
  • Schroer K , Peter Luef K, Stefan Hartner F, Glieder A, Pscheidt B. Engineering the pichia pastoris methanol oxidation pathway for improved NADH regeneration during whole-cell biotransformation. Metab. Eng. 12(1), 8–17 (2009).
  • Long A , WardOP. Biotransformation of benzaldehyde by Saccharomyces cerevisiae: characterization of the fermentation and toxicity effects of substrates and products. Biotechnol. Bioeng. 34(7), 933–941 (1989).
  • Zocher F , EnzelbergerMM, BornscheuerUT, HauerB, WohllebenW, SchmidRD: Epoxide hydrolase activity of streptomyces strains. J. Biotechnol. 77(2–3), 287–292 (2000).
  • Li C , LiuQ, SongX, DiD, JiA, QuY. Epoxide hydrolase-catalyzed resolution of ethyl 3-phenylglycidate using whole cells of Pseudomonas sp. Biotechnol. Lett. 25(24), 2113–2116 (2003).
  • Xu Y , XuJH, PanJ, TangYF. Biocatalytic resolution of glycidyl aryl ethers by trichosporon loubierii: cell/substrate ratio influences the optical purity of (r)-epoxides. Biotechnol. Lett. 26(15), 1217–1221 (2004).
  • Kotik M , BrichacJ, KyslikP. Novel microbial epoxide hydrolases for biohydrolysis of glycidyl derivatives. J. Biotechnol. 120(4), 364–375 (2005).
  • Liu Y , ShaQ, WuS, WangJ, YangL, SunW. Enzymatic resolution of racemic phenyloxirane by a novel epoxide hydrolase from aspergillus niger SQ-6 and its fed-batch fermentation. J. Ind Microbiol. Biotechnol. 33(4), 274–282 (2006).
  • Labuschagne M , AlbertynJ. Cloning of an epoxide hydrolase-encoding gene from rhodotorula mucilaginosa and functional expression in yarrowia lipolytica. Yeast24(2), 69–78 (2007).
  • Hwang YO , KangSG, WooJHet al. Screening enantioselective epoxide hydrolase activities from marine microorganisms: detection of activities in erythrobacter spp. Mar. Biotechnol. 10(4), 366–373 (2008).
  • Phillips IR , ShephardEA. Flavin-containing monooxygenases: mutations, disease and drug response. Trends. Pharmacol. Sci. 29(6), 294–301 (2008).
  • Crettol S , PetrovicN, MurrayM. Pharmacogenetics of phase I and phase II drug metabolism. Curr. Pharm. Des. 16(2), 204–219 (2010).
  • Iyanagi T . Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification. Int. Rev. Cytol. 260, 35–112 (2007).
  • Williams JA , HylandR, JonesBCet al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/auc) ratios. Drug Metab. Dispos. 32(11), 1201–1208 (2004).
  • Mackenzie PI , BockKW, BurchellBet al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet. Genomics15(10), 677–685 (2005).
  • Tukey RH , StrassburgCP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 40, 581–616 (2000).
  • Bock KW , KöhleC. Topological aspects of oligomeric UDP-glucuronosyltransferases in endoplasmic reticulum membranes: advances and open questions. Biochem Pharmacol. 77(9), 1458–1465 (2009).
  • Radominska-Pandya A , BrattonS, LittleJM. A historical overview of the heterologous expression of mammalian UDP-glucuronosyltransferase isoforms over the past twenty years. Curr. Drug Metab. 6(2), 141–160 (2005).
  • Coller JK , ChristrupLL, SomogyiAA. Role of active metabolites in the use of opioids. Eur. J. Clin. Pharmacol. 65(2), 121–139 (2009).
  • Stachulski AV : The chemistry and biological activity of acyl glucuronides. Curr. Opin. Drug Discov. Devel. 10(1), 58–66 (2007).
  • Ritter JK . Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem. Biol. Interact. 129(1–2), 171–193 (2000).
  • Schulz C , BoeckS, HeinemannV, StemmlerHJ. UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy? Anticancer Drugs20(10), 867–879 (2009).
  • Saudan C , BaumeN, RobinsonN, AvoisL, ManginP, SaugyM. Testosterone and doping control. Br. J. Sports. Med. 40 (Suppl. 1), i21–i24 (2006).
  • Alonen A , GartmanM, AitioO, FinelM, Yli-KauhaluomaJ, KostiainenR. Synthesis, structure characterization, and enzyme screening of clenbuterol glucuronides. Eur. J. Pharm. Sci. 37(5), 581–587 (2009).
  • Thevis M , OpfermannG, SchmicklerH, SchanzerW. Mass spectrometry of steroid glucuronide conjugates. Ii-electron impact fragmentation of 3-keto-4-en- and 3-keto-5 α-steroid-17-o-β glucuronides and 5 α-steroid-3 α,17β-diol 3- and 17-glucuronides. J. Mass. Spectrom. 36(9), 998–1012 (2001).
  • Dell D . Labile metabolites. Chromatographia59, S139–S148 (2004).
  • Johnson CH , WilsonID, HardingJRet al. NMR spectroscopic studies on the in vitro acyl glucuronide migration kinetics of ibuprofen ((+/-)-(r,s)-2-(4-isobutylphenyl) propanoic acid), its metabolites, and analogues. Anal. Chem. 79(22), 8720–8727 (2007).
  • Kenny JR , MaggsJL, MengXet al. Syntheses and characterization of the acyl glucuronide and hydroxy metabolites of diclofenac. J. Med. Chem. 47(11), 2816–2825 (2004).
  • Meng X , MaggsJL, Pryde Dcet al. Cyclization of the acyl glucuronide metabolite of a neutral endopeptidase inhibitor to an electrophilic glutarimide: synthesis, reactivity, and mechanistic analysis. J. Med. Chem. 50(24), 6165–6176 (2007).
  • Al-Zoughool M , TalaskaG. High performance liquid chromatography method for determination of N-glucuronidation of 4-aminobiphenyl by mouse, rat, and human liver microsomes. Anal. Biochem. 340(2), 352–358 (2005).
  • Luo H , HawesEM, MckayG, MidhaKK. Synthesis and characterization of quaternary ammonium-linked glucuronide metabolites of drugs with an aliphatic tertiary amine group. J. Pharm. Sci. 81(11), 1079–1083 (1992).
  • Mutlib AE , NelsonWL. Synthesis and identification of the N-glucuronides of norgallopamil and norverapamil, unusual metabolites of gallopamil and verapamil. J. Pharmacol. Exp. Ther. 252(2), 593–599 (1990).
  • Vashishtha SC , HawesEM, MckayG, MccannDJ. Synthesis and identification of the quaternary ammonium-linked glucuronide of 1-phenylimidazole in human liver microsomes and investigation of the human UDP-glucuronosyltransferases involved. Drug Metab. Dispos. 28(9), 1009–1013 (2000).
  • Pallmann T , JonasU, WagnerMet al. Enzyme-assisted synthesis and structural characterization of pure benzodiazepine glucuronide epimers. Eur. J. Pharm. Sci. 29, 29 (2009).
  • Anderson S , Luffer-AtlasD, KnadlerMP. Predicting circulating human metabolites: how good are we? Chem. Res. Toxicol. 22(2), 243–256 (2009).
  • Dragan CA , BuchheitD, BischoffD, EbnerT, BureikM. Glucuronide production by whole-cell biotransformation using genetically engineered fission yeast schizosaccharomyces pombe. Drug Metab. Dispos. 38(3), 509–515 (2010).
  • Amadio J , MurphyCD. Biotransformation of fluorobiphenyl by cunninghamella elegans. Appl. Microbiol. Biotechnol. 3, 3 (2009).
  • Collier AC , KeelanJA, Van Zijl PE, Paxton JW, Mitchell MD, Tingle MD. Human placental glucuronidation and transport of 3´azido-3´-deoxythymidine and uridine diphosphate glucuronic acid. Drug Metab. Dispos. 32(8), 813–820 (2004).
  • Freiser H , JiangQ. Optimization of the enzymatic hydrolysis and analysis of plasma conjugated γ-CEHC and sulfated long-chain carboxychromanols, metabolites of vitamin E. Anal. Biochem. 388(2), 260–265 (2009).
  • Liu X , TamVH, HuM. Disposition of flavonoids via enteric recycling: determination of the UDP-glucuronosyltransferase isoforms responsible for the metabolism of flavonoids in intact CACO-2 TC7 cells using sirna. Mol. Pharm. 4(6), 873–882 (2007).
  • Bai X , XieYY, LiuJ, QuJL, KanoY, YuanD. Isolation and identification of urinary metabolites of kakkalide in rats. Drug Metab. Dispos. 38(2), 281–286 (2010).
  • Zhang ZF , LiuY, LuoP, ZhangH. Separation and purification of two flavone glucuronides from erigeron multiradiatus (lindl.) benth with macroporous resins. J. Biomed. Biotechnol. 11, 875629 (2009).
  • Kittelmann M , RheineggerU, EspigatAet al. Preparative enzymatic synthesis of the acylglucuronide of mycophenolic acid. Biocatalysis345(6–7), 825–829 (2003).
  • Caron P , TrottierJ, VerreaultM, BelangerJ, KaedingJ, BarbierO. Enzymatic production of bile acid glucuronides used as analytical standards for liquid chromatography-mass spectrometry analyses. Mol. Pharm. 3(3), 293–302 (2006).
  • Schwaninger AE , MeyerMR, ZappJ, MaurerHH. The role of human UDP glucuronyltransferases on the formation of the methylenedioxymethamphetamine (ecstasy) phase II metabolites r- and s-3-methoxymethamphetamine 4-O-glucuronides. Drug Metab. Dispos. 37(11), 2212–2220 (2009).
  • Fujita K , MogamiA, HayashiA, KamatakiT. Establishment of Salmonella strain expressing catalytically active human UDP-glucuronosyltransferase 1A1 (UGT1A1). Life Sci. 66(20), 1955–1967 (2000).
  • Dellinger RW , ChenG, Blevins-PrimeauAS, KrzeminskiJ, AminS, LazarusP. Glucuronidation of phip and n-oh-phip by UDP-glucuronosyltransferase 1A10. Carcinogenesis28(11), 2412–2418 (2007).
  • Fisher MB , PaineMF, StrelevitzTJ, WrightonSA. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab. Rev. 33(3–4), 273–297 (2001).
  • Liu J , BalasubramanianMK. 1,3-β-glucan synthase: a useful target for antifungal drugs. Curr. Drug Targets Infect. Disord. 1(2), 159–169 (2001).
  • Tanaka N , KonomiM, OsumiM, TakegawaK. Characterization of schizosaccharomyces pombe mutant deficient in UDP-galactose transport activity. Yeast18(10), 903–914 (2001).
  • Passarinha LA , BonifacioMJ, QueirozJA. Application of a fed-batch bioprocess for the heterologous production of hscomt in Escherichia coli. J. Microbiol. Biotechnol. 19(9), 972–981 (2009).
  • Passarinha LA , BonifacioMJ, Soares-Da-SilvaP, QueirozJA. A new approach on the purification of recombinant human soluble catechol-O-methyltransferase from an Escherichia coli extract using hydrophobic interaction chromatography. J. Chromatogr. A1177(2), 287–296 (2008).
  • Wang H , VathGM, KawamuraAet al. Over-expression, purification, and characterization of recombinant human arylamine N-acetyltransferase 1. Protein J. 24(2), 65–77 (2005).
  • Riches Z , BloomerJC, CoughtrieMW. Comparison of 2-aminophenol and 4-nitrophenol as in vitro probe substrates for the major human hepatic sulfotransferase, sult1A1, demonstrates improved selectivity with 2-aminophenol. Biochem. Pharmacol. 74(2), 352–358 (2007).
  • Ingelman-Sundberg M . Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci. 25(4), 193–200 (2004).
  • Daly AK . Pharmacogenetics and pharmacogenomics. Pharmacogenomics8(11), 1493–1496 (2007).
  • Rodriguez-Antona C , JandeM, RaneA, Ingelman-SundbergM. Identification and phenotype characterization of two cyp3a haplotypes causing different enzymatic capacity in fetal livers. Clin. Pharmacol. Ther. 77(4), 259–270 (2005).
  • Dai D , TangJ, RoseRet al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J. Pharmacol. Exp. Ther. 299(3), 825–831 (2001).
  • Blaisdell J , Jorge-NebertLF, CoulterSet al. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics14(8), 527–537 (2004).
  • Kirchheiner J , KleinC, MeinekeIet al. Bupropion and 4-oh-bupropion pharmacokinetics in relation to genetic polymorphisms in cyp2B6. Pharmacogenetics. 13(10), 619–626 (2003).
  • Komori M , NishioK, OhiH, KitadaM, KamatakiT. Molecular cloning and sequence analysis of CDNA containing the entire coding region for human fetal liver cytochrome P450. J. Biochem. 105(2), 161–163 (1989).
  • Domanski TL , FintaC, HalpertJR, ZaphiropoulosPG. CDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol. Pharmacol. 59(2), 386–392 (2001).
  • Westlind A , MalmeboS, JohanssonIet al. Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43. Biochem. Biophys. Res. Commun. 281(5), 1349–1355 (2001).
  • Gellner K , EiseltR, HustertEet al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics. 11(2), 111–121 (2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.